CVS invests in community health
CVS is bolstering its effort to transform itself into an integrated pharmacy health care company with a big grant.
The company's Health Foundation has extended its commitment to the National Association of Free & Charitable Clinics with $1 million in new grants to 49 Free and Charitable Clinics across the country. The new grants will focus on improving health outcomes for patients managing chronic conditions such as diabetes and hypertension.
"The rising cost of health care can make finding quality and affordable care harder to come by for many Americans," said Eileen Howard Boone, president of the CVS Health Foundation. "Through our support of the National Association of Free & Charitable Clinics, we're able to increase access to quality care, improve chronic disease management and care coordination to help improve health outcomes for the most vulnerable patients and reduce health care costs in the communities we serve."
The new funds, which bring the Foundation's total contribution to NAFC to more than $4.5 million since 2015, will support increased access to quality care, as well as chronic disease management and prevention services. Grants, ranging from $10,000 to $20,000, will be distributed to 49 free and charitable clinics.
"The NAFC and our network of charitable health care providers are beyond grateful for the continued support and unwavering commitment we receive from the CVS Health Foundation," said Nicole Lamoureux, NAFC CEO. "Diabetes and hypertension are the top two diagnoses found among our patient population. This year's funding will allow our Free and Charitable Clinics to focus on improving their patients' health outcomes for these chronic conditions, and in turn improving the health of communities across the country."
CVS Health still expects its $69 billion acquisition of Aetna to close in the second half of the year despite the Department of Justice's request for more information.
On Tuesday the American Medical Association issued a statement on the deal:
"The AMA strongly encourages a rigorous review of the proposed merger by state and federal officials given its potential negative impact on pharmaceutical benefit management services, local health insurance markets, as well as local retail pharmacy markets, which in turn can harm consumers in these markets,” AMA President David O. Barbe said Tuesday afternoon. “Close scrutiny is needed to determine if the ramifications of this massive merger will threaten the benefits of competition, including increased access and choice, lower prices and higher quality care for patients.”